Technical Safety Services Private Equity: Top Firms in 2026

Key Facts

• Levine Leichtman Capital Partners (LLCP) acquired Technical Safety Services (TSS) from The Edgewater Funds and JZ Partners in June 2022 in a secondary buyout, making it the landmark transaction defining PE activity in the TICC sector.
• LLCP manages $9.3 billion in assets under management as of September 2023, with its latest fund, Fund VII, closing at over $3.6 billion in capital commitments despite one of the most challenging fundraising environments in recent history.
• TSS completed more than 29 add-on acquisitions total across its two PE ownership periods, including international expansion with the acquisition of Clean Air Technologies in Kent, UK in January 2024.
• The TICC sector serves pharmaceutical, biotechnology, and healthcare end markets with testing, inspection, certification, and calibration services that are compliance-mandated and non-deferrable across facility lifecycles.
• PE investment in technical safety services is supported by three structural tailwinds: stricter FDA and GMP enforcement, increased biotech R&D spending, and more rigorous sterile compounding pharmacy regulations.
• Active PE investors in this space span Los Angeles, Chicago, New York, Boston, and Dallas, with platform assets from TSS extending nationally and into the UK and Europe.

TICC Market Overview

Technical safety services private equity refers to the segment of PE investment targeting middle-market companies that provide testing, inspection, certification, and calibration services, commonly abbreviated as TICC, to pharmaceutical, biotechnology, and healthcare facilities. These businesses operate in controlled environments, including clean rooms, bio-safety cabinets, medical gas systems, high-purity water systems, and laboratory equipment. Each requires compliance validation at regular, mandated intervals. The services cannot be delayed or deferred by customers without triggering regulatory violations, creating a reliable, recurring revenue base that is structurally attractive to fund managers.

Regulatory bodies including the FDA, ISO, and GMP standards authorities require life sciences facilities to certify and recertify controlled environments on set schedules. Stricter enforcement tied to sterile compounding pharmacy regulations has expanded the required compliance footprint. Accelerating private investment in lab facilities and biotech R&D has broadened the addressable customer base. These forces collectively reduce revenue cyclicality relative to most service industries.

The TICC sector remains highly fragmented, with hundreds of regional and local service providers and no dominant national player. This fragmentation creates a natural buy-and-build opportunity for PE investors. Platform companies can acquire regional specialists and extend geographic coverage. EBITDA (earnings before interest, taxes, depreciation, and amortization) grows through both organic service expansion and bolt-on acquisitions at favorable entry multiples. TSS, originally headquartered in La Jolla, California, exemplifies this playbook. The company scaled from a regional provider to a nationally distributed platform with European operations under successive PE ownership.

Firm Comparison at a Glance

The firms below represent the most active and sector-aligned PE investors in technical safety, TICC, and adjacent healthcare and business services segments of the middle market. AUM figures are drawn from the most recent publicly available disclosures.

LLCP and THL Partners represent the largest fund sizes in the group, while Ampersand and Linden offer the most focused life sciences mandates. Edgewater's track record building TSS from scratch gives it a unique proof point in the TICC niche specifically.

Top Picks by Investment Strategy

Largest AUM in the Space: Levine Leichtman Capital Partners. LLCP's $9.3 billion in assets and oversubscribed Fund VII close demonstrate institutional conviction in its structured PE model. It is the only firm with a directly documented TICC platform investment, making it the reference point for this niche.

TICC Sector Specialist: The Edgewater Funds. Edgewater built Technical Safety Services from a regional provider into a national platform through more than 20 add-on acquisitions between 2018 and 2022, representing the most detailed documented track record in TICC services consolidation.

Healthcare-Only Mandate: Linden Capital Partners. With over $5 billion invested cumulatively and a focus exclusively on healthcare services, pharma services, and outsourced clinical businesses, Linden offers unmatched sector depth for companies serving regulated life sciences facilities.

Life Sciences Growth Equity Leader: Ampersand Capital Partners. Ampersand's $3 billion under management is deployed exclusively into middle-market laboratory products, contract manufacturing, and pharma services companies, making it the natural home for TICC-adjacent businesses in the growth equity stage.

Strongest Diversified Platform for Sellers: Charlesbank Capital Partners. Charlesbank combines $20 billion in AUM with deep expertise across business services, healthcare, and industrial services, offering sellers broad network leverage alongside sector-specific knowledge.

Best for Lower Middle-Market Entry: New Harbor Capital. New Harbor's $10–$40 million per-transaction deal range and specific focus on healthcare services and tech-enabled business services makes it the most accessible institutional investor for smaller technical safety businesses beginning a PE process.

Management-Centric Co-Investment: JZ Partners. JZ's management-centric investment policy, backed by more than 300 investments and $4 billion in aggregate capital since 1986, suits founders who prioritize strategic partnership over aggressive operational restructuring.

Top Firms in Detail

Levine Leichtman Capital Partners (LLCP)

The defining PE investor in technical safety services, LLCP operates with $9.3 billion in assets and a differentiated approach it calls Structured Private Equity. This model combines subordinated debt, preferred equity, and common equity to give management teams growth capital with less dilution than a traditional buyout. The TSS acquisition from Edgewater and JZ Partners in June 2022 was Fund VI's ninth platform investment, establishing LLCP as the sector's most visible general partner in TICC. Under LLCP's ownership, TSS completed at least seven additional acquisitions. These included Controlled Environment Management in Arizona in September 2023 and Clean Air Technologies in Kent, UK in January 2024, marking TSS's first European deal. Fund VII's close at over $3.6 billion exceeded its target despite difficult fundraising conditions, reflecting strong limited partner re-up rates. LLCP's nine partners average 19 years of tenure at the firm, providing deal continuity that management sellers can evaluate concretely.

The Edgewater Funds

Edgewater's claim to this niche is singular: the firm built Technical Safety Services from the ground up after acquiring the platform in 2018 and scaling it through more than 20 add-on acquisitions before achieving a successful secondary exit to LLCP in June 2022. That four-year hold period with a documented build-and-sell outcome is the clearest track record evidence in the TICC space. Headquartered in Chicago, Edgewater targets middle-market companies with $20 million to $500 million in revenue and $5 million to $30 million in EBITDA, deploying growth capital and traditional buyout structures depending on the situation. The firm has raised $2.8 billion in capital commitments since 2001 across its Edgewater Growth Capital Partners funds. Edgewater's hands-on add-on sourcing approach is directly applicable to founders considering a first institutional round in inspection or certification services.

JZ Partners

JZ's role in the TSS story reflects its broader investment philosophy. The Chicago and New York-based firm co-invested alongside Edgewater as a minority capital partner, consistent with its management-centric investment policy. That policy prioritizes collaborative strategic planning over control-oriented restructuring. The firm and its principals have completed more than 300 investments representing over $4 billion in aggregate since 1986, demonstrating long institutional continuity across economic cycles. JZ does not publish individual fund sizes, but the aggregate capital base indicates a substantial committed LP base. For TICC businesses where founder relationships and management team continuity are strategic priorities, JZ's non-control, partnership-oriented model is a meaningful differentiator from sponsors who require majority ownership.

THL Partners (Thomas H. Lee Partners)

THL Partners brings the largest historical fund scale to this sector comparison, with over $30 billion raised since the firm's founding in 1974 and a Fund IX close at $5.6 billion. The Boston-based firm focuses its current investment activity across healthcare, financial technology and services, and technology and business solutions, all three of which intersect with TICC-adjacent service businesses. A separately raised $900 million Automation Fund signals THL's appetite for technology-enabled service platforms. This is relevant to TICC businesses incorporating digital calibration and remote monitoring capabilities. THL acquired Nextech Systems in healthcare IT and Insurance Technologies (Hexure), demonstrating an ability to close large-scale healthcare and technology services transactions. For healthcare services companies with revenues above the traditional mid-market range, THL's fund size and sector coverage offer a credible path.

Charlesbank Capital Partners

Charlesbank's $20 billion in AUM places it among the larger mid-market buyout firms in this comparison, and its sector coverage spans business and consumer services, healthcare, industrials, and technology infrastructure. That breadth makes it a natural fit for technical safety services companies that straddle multiple end markets, such as platforms serving both pharma and industrial inspection clients. Charlesbank is headquartered in Boston and operates as a generalist-leaning mid-market buyout firm with sufficient sector depth in healthcare and services to evaluate regulated compliance businesses. Sellers who have outgrown specialist firms like Edgewater or New Harbor may want a buyer with genuine sector knowledge rather than a sector-agnostic fund. Charlesbank's combination of scale and specialization addresses that gap.

Ampersand Capital Partners

Ampersand Capital is the most focused life sciences investor in this group. The Boston-based firm deploys its $3 billion exclusively into middle-market growth investments in laboratory products and services, contract manufacturing, and pharmaceutical services. This positions Ampersand directly adjacent to TICC businesses serving the same pharmaceutical and biotech end markets. Ampersand invests at the growth equity stage, typically taking minority or structured positions in companies with established revenues rather than executing control buyouts. This approach suits founders who want to retain operational leadership. Its mandate covers laboratory services infrastructure broadly, encompassing the calibration, certification, and compliance testing verticals that define technical safety services.

Linden Capital Partners

One of the largest dedicated healthcare-only PE firms in the middle market, Linden Capital has invested more than $5 billion cumulatively across healthcare services, pharma services, and outsourced clinical businesses. The Chicago-based firm's singular sector focus means its deal team brings pharma services expertise to due diligence, portfolio support, and M&A sourcing. Generalist funds cannot replicate that depth. For compliance-services companies whose primary revenue comes from pharmaceutical and biotech facilities, Linden offers a built-in network of pharma services executives and operational advisors. Its buyout strategy targets control investments with clear platform-building potential.

New Harbor Capital

New Harbor occupies the lower end of the middle market with a $10–$40 million per-transaction investment range, making it one of the few institutional PE firms explicitly targeting smaller healthcare services and tech-enabled business services companies. The Chicago-based firm has backed Escalon Services in tech-enabled business services, Bloom Health Centers in mental healthcare, and Respire Homecare Services, demonstrating a pattern of building sector-focused platforms from smaller entry points. Businesses generating $3–$10 million in EBITDA that are too small for LLCP or Edgewater's current mandates fit naturally within New Harbor's deal parameters. The firm's healthcare orientation and buy-and-build approach align closely with the TICC consolidation thesis.

Investment Trends and Capital Flows

Buy-and-Build Consolidation Dominates Deal Activity

The TICC services market remains highly fragmented, with no single operator controlling more than a small percentage of regional demand. TSS's trajectory illustrates the typical playbook: Edgewater executed more than 20 add-on acquisitions between 2018 and 2022, and LLCP continued with at least seven more after acquiring the platform, including Controlled Environment Management in Arizona and Quality Systems Integration in Massachusetts. Roll-up strategies allow platforms to build national coverage, cross-sell services to existing clients, and generate EBITDA accretion on each acquisition at favorable entry multiples.

Regulatory Tailwinds Create Structural Revenue Floors

FDA enforcement of good manufacturing practice (GMP) standards requires pharmaceutical and biotech facilities to certify controlled environments at mandated intervals regardless of business conditions. Stricter sterile compounding pharmacy regulations added another layer of required compliance testing after high-profile contamination incidents increased regulatory scrutiny. These mandates convert TICC service contracts from discretionary vendor relationships into compliance obligations, supporting pricing power and customer retention.

International Expansion Opens a New Growth Phase

TSS's acquisition of Clean Air Technologies in Kent, UK in January 2024 marked the first European step for a PE-backed TICC platform built primarily on US acquisitions. Cross-border expansion extends the addressable market for compliance services into pharmaceutical clusters in the UK and continental Europe, where similar GMP and ISO standards create comparable service demand. PE firms with global offices, including LLCP with offices in London, Stockholm, The Hague, and Frankfurt, are better positioned to source and execute European bolt-on deals.

Biotech R&D Investment Expands the Addressable Market

Increased private investment in laboratory facilities and sustained growth in biotech R&D spending have created new TICC service demand from smaller biopharma companies establishing GMP-compliant production and testing environments for the first time. These new entrants typically require full facility commissioning, clean room validation, and ongoing calibration contracts, extending the revenue lifecycle well beyond initial setup. This dynamic is particularly relevant to platforms with facility commissioning capabilities, such as TSS's Cornerstone Commissioning subsidiary.

Defensive Portfolio Positioning Drives LP Demand

Limited partners allocating to PE funds increasingly favor portfolio companies with non-deferrable revenue streams. These are businesses that hold up during economic contractions. LLCP Fund VII was oversubscribed despite what the firm described as one of the most challenging fundraising environments in recent history. This signals that LP demand for resilient service businesses remains strong. TICC companies, with contractual compliance schedules that clients cannot legally postpone, represent a compelling answer to LP requests for defensive portfolio exposure.

How to Evaluate PE Investors in This Space

Track record in the specific sector is the most reliable predictor of value-add. Review whether a firm has previously owned a platform in TICC, healthcare services, or compliance-driven business services. Examine how many add-on acquisitions that platform completed, at what pace, and with what outcome. LLCP's documented TSS acquisition history and Edgewater's prior TSS build-out provide public benchmarks for what effective sector experience looks like.

Investment structure matters more in this niche than in many others. LLCP's Structured Private Equity approach combines subordinated debt, preferred equity, and common equity. It offers management teams less dilution than a traditional leveraged buyout (LBO). In an LBO, the general partner takes majority equity and uses significant debt to fund the acquisition. Founders retaining meaningful equity stakes should model both structures before selecting a buyer.

Fund size relative to company size determines how much operational attention a portfolio company receives. Edgewater's $5–$30 million EBITDA target range puts smaller platforms at the center of its mandate. LLCP and THL Partners operate at higher revenue thresholds, where platforms of that size become growth priorities rather than core assets. Misalignment between your company's scale and the firm's typical deal size is a common source of post-close underperformance.

Partner tenure provides a meaningful proxy for institutional stability. LLCP's nine partners average 19 years at the firm. This continuity reduces the risk of mid-hold leadership changes that disrupt deal execution or strategic priorities. Firms with frequent partner turnover or recent spin-outs may carry integration risk that is difficult to assess before a deal closes.

Operational value-add should be evaluated concretely rather than taken at face value. Ask prospective investors for references from portfolio company CEOs on M&A sourcing support, geographic expansion playbooks, and management team recruitment. The difference between a sponsor who facilitates add-on acquisitions and one who merely approves them is significant. This distinction can determine whether a buy-and-build thesis delivers at exit.

Which Firm Fits Your Needs?

Management teams and founders considering a recapitalization or PE partnership in TICC should evaluate LLCP and Edgewater as primary reference points. LLCP's structured equity model reduces dilution at entry, and its international office network supports global expansion ambitions. Edgewater suits earlier-stage platforms where the add-on acquisition pipeline needs to be built from a smaller base. Its target entry point is $5–$30 million in EBITDA.

Healthcare services business owners whose primary customers are pharmaceutical and biotech facilities have stronger sector network options at Ampersand Capital Partners and Linden Capital Partners than at generalist funds. Ampersand's growth equity approach preserves founder ownership stakes while providing capital for laboratory services expansion. Linden's healthcare-only buyout mandate brings a deal team that understands pharma facility compliance, removing the need for extensive education during due diligence.

LPs building diversified alternatives portfolios can use LLCP Fund VII's oversubscribed close as a signal of investor conviction. The fund exceeded its target despite a difficult fundraising environment, with strong re-up rates from prior LP relationships. Charlesbank and THL Partners offer broader sector coverage within similar mid-market buyout mandates. LPs seeking business services and healthcare exposure across multiple end markets have strong options in both.

Methodology

This guide to technical safety services private equity was compiled using public press releases, firm websites, PE industry deal databases, and web research. Firms were selected based on documented investments in TICC, healthcare services, or compliance-driven business services at the middle-market level, with additional firms included where sector focus, fund size, and investment stage indicated high relevance to companies in the technical safety services space. AUM figures and fund sizes reflect the most recent publicly disclosed data, primarily from 2022 through 2024 reporting periods. Not all fund sizes and deal multiples are publicly available; where data was not confirmed, it has been omitted rather than estimated. This list is representative of active investors in the space and is not exhaustive.